Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Can J Physiol Pharmacol. 2009 Dec;87(12):1102-9. doi: 10.1139/Y09-109.
U74389F is a compound in a family of 21-aminosteroids devoid of classical glucocorticoid action that inhibit lipid peroxidation. These compounds improve neurologic function and tissue survival after head or spinal cord injury. Dexamethasone inhibits development of intimal hyperplasia (IH) and improves attenuated nitric oxide (NO) production of the rabbit aorta subsequent to balloon catheter injury. We tested the hypothesis that U74389F is protective in a catheter-induced endothelial-denuded and arterial injury model. A 4-Fr Fogarty balloon (BALL) embolectomy catheter was passed through the thoracic aorta of New Zealand White rabbits treated with 15 mg/kg U74389F (LAZ) 2 days before and 1 week after injury. Animals were killed at 4 weeks after surgical intervention, and formation of IH was determined by calculating the intimal/medial ratio (I/M). The treatment groups of animals were injured untreated (BALL), injured treated (BALL/LAZ), uninjured treated (CONTROL/LAZ), and sham-operated treated (SHAM/LAZ). Scanning electron microscopy revealed that after injury lazaroid treatment produced an improvement of the neoendothelium (alignment in the direction of blood and fewer intercellular gaps) as compared with injured but untreated aortas. Relaxation to acetylcholine (NO formation) was impaired in aortic rings from catheterized animals; lazaroid treatment improved the relaxation to 10-6 mol/L acetylcholine but not to lower concentrations. I/M for SHAM/LAZ, BALL, and BALL/LAZ was 0.02 +/- 0.02, 21.6 +/- 1.6, and 17.2 +/- 2.5, respectively; BALL vs. BALL/LAZ, p < 0.06. An increased contractile response to 120 mmol/L KCl was observed after lazaroid treatment. This is the first report of lazaroid-mediated improvement in the neoendothelial morphology, improved neoendothelial NO generation, and augmented hypopolarizing contractile response, but no attenuation in the development of IH.
U74389F 是 21-氨基甾体家族中的一种化合物,没有经典的糖皮质激素作用,能抑制脂质过氧化。这些化合物可改善颅脑或脊髓损伤后的神经功能和组织存活率。地塞米松抑制内膜增生 (IH) 的发展,并改善兔主动脉在球囊导管损伤后减弱的一氧化氮 (NO) 产生。我们检验了以下假设,即在导管诱导的内皮剥脱和动脉损伤模型中 U74389F 具有保护作用。新西兰白兔经 15mg/kg U74389F (LAZ) 预处理 2 天和损伤后 1 周,用 4Fr Fogarty 球囊(BALL)取栓导管穿过胸主动脉。动物在外科干预后 4 周处死,通过计算内膜/中膜比 (I/M) 来确定 IH 的形成。动物的治疗组包括未损伤未治疗组(BALL)、损伤治疗组(BALL/LAZ)、未损伤治疗组(CONTROL/LAZ)和假手术治疗组(SHAM/LAZ)。扫描电子显微镜显示,与未经治疗的损伤主动脉相比,拉泽罗特治疗后新生内皮(沿血流方向排列且细胞间间隙较少)得到改善。来自导管化动物的主动脉环对乙酰胆碱的舒张(NO 形成)受损;拉泽罗特治疗改善了对 10-6mol/L 乙酰胆碱的舒张,但对较低浓度的乙酰胆碱无作用。SHAM/LAZ、BALL 和 BALL/LAZ 的 I/M 分别为 0.02 +/- 0.02、21.6 +/- 1.6 和 17.2 +/- 2.5;BALL 与 BALL/LAZ 相比,p<0.06。拉泽罗特治疗后观察到对 120mmol/L KCl 的收缩反应增加。这是拉泽罗特治疗改善新生内皮形态、增强新生内皮 NO 生成和增强去极化收缩反应的首次报道,但 IH 的发展没有减弱。